In parallel, the anti-IL-23p40 antibody (Ustekinumab) [132,133] and anti-IL-23p19 antibodies (guselkumab, risankizumab, and tildrakizumab) [133,134,135] exhibit a high efficacy to psoriasis with a superiority of risankizumab over ustekinumab [133], and guselkumab over the anti-TNF-α antibody adalimumab [134]. This evidence concerns the gene IL23A and psoriasis.